Business
Mymetics' HIV Vaccine Candidate Confirms Promise in Preclinical Study With the Texas Biomedical Research Institute
Mymetics' HIV Vaccine Candidate Confirms Promise in Preclinical Study With the Texas Biomedical Research Institute.
About this update from Mymetics Corp.
[{"type":"text","content":"\n \n \n Mymetics' HIV Vaccine Candidate Confirms Promise in Preclinical Study With the Texas Biomedical Research Institute\n \n \nMymetics' HIV Vaccine Candidate Confirms Promise in Preclinical Study With the Texas Biomedical Research Institute\n \n EPALINGES, SWITZERLAND--(Marketwired - Apr 11, 2016) - Mymetics Corporation (OTCQB:MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate has shown to generate significant protection in groups of twelve female monkeys against repeated AIDS virus exposures during part of the preclinical study.\n The blinded study was led by Dr. Ruth Ruprecht, Scientist & Director of the Texas Biomed AIDS Research Program and was funded by the Bill & Melinda Gates foundation. During the first part of the study the Mymetics' two-component virosome-based HIV vaccine was able to show significant efficacy of 87% in delaying the time to persistent infection versus the control group after 7 intravaginal virus challenges. The study aimed to mimic the exposure of women to semen from HIV-infected men, although the viral dose of each of these 7 animal challenges represented about 70,000 times the average human HIV dose passed during sexual intercourse from an HIV-infected male to an uninfected female. \n During the second part of the study the animal viral challenge dose was increased by 50% starting from the 8th challenge onward, reaching more than 100,000 times the average amount of virus passed from an infected man to a female partner. At this virus dose, the vaccine did not show significant protection in the animals as the immune system was overloaded.\n Dr. Ruth Ruprecht said, \"We are encouraged by the initial strong protection provided by the vaccine candidate, which is in line with the results from an earlier primate study performed in China that we were asked to repeat. The fact that the vaccine-induced immune defenses were eventually overcome requires a careful analysis to understand the mechanisms of the initial vaccine action and to learn what other immune defenses can be enlisted to yield even more potent antiviral action.\" \n Sylvain Fleury, CSO of Mymetics, commented, \"We are pleased that Mymetics HIV virosome-based vaccine could s...